Albuterol Sulfate Metered Dose Inhalers Market Report 2025

The albuterol sulfate metered dose inhalers market size has grown strongly in recent years. It will grow from $4.78 billion in 2024 to $5.15 billion in 2025 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to rising awareness of respiratory health, growing adoption of fast-relief bronchodilators, growing demand for portable inhalation devices, rising incidence of respiratory emergencies, and increasing approvals of generic inhalers.

The albuterol sulfate metered dose inhalers market size is expected to see strong growth in the next few years. It will grow to $7.04 billion in 2029 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to rising demand for cost-effective treatment options, increasing focus on preventive respiratory care, increasing investments in inhaler innovation, rising awareness campaigns by health organizations, and growing prevalence of respiratory allergies. Major trends in the forecast period include innovation in drug formulation for enhanced efficacy, integration of digital dose tracking systems, advanced manufacturing techniques for consistent dosing, innovation in eco-friendly propellants, and integration of telemedicine with inhaler use.

The forecast of 8.1% growth over the next five years reflects a modest reduction of 0.3% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden U.S. pulmonary clinics by driving up costs of albuterol sulfate MDIs sourced from India and China, exacerbating asthma management expenses and increasing respiratory care burdens for millions of patients. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The growing prevalence of respiratory conditions is anticipated to drive the expansion of the albuterol sulfate metered-dose inhalers market. Respiratory illnesses affect the lungs and airways, causing breathing difficulties and reduced oxygen intake. These conditions include asthma, chronic obstructive pulmonary disease (COPD), pneumonia, bronchitis, and other lung infections. One of the major contributors to the increase in respiratory conditions is rising air pollution, which heightens exposure to harmful pollutants that irritate the airways and deteriorate lung function. Albuterol sulfate metered-dose inhalers help alleviate symptoms by relaxing airway muscles, enhancing airflow, and easing breathing. These inhalers provide immediate relief from wheezing, coughing, and shortness of breath. For example, according to the Australian Bureau of Statistics in December 2023, the prevalence of COPD in Australia increased from 2.4% in 2021 to 2.5% in 2022. Thus, the growing occurrence of respiratory conditions is fueling the demand for albuterol sulfate metered-dose inhalers.

Leading companies in the albuterol sulfate metered-dose inhalers market are prioritizing the development of advanced solutions, including generic inhalation products, to increase accessibility for individuals with chronic respiratory issues. These generic inhalers offer the same active ingredients, dosages, and therapeutic benefits as branded products but are typically more affordable. For instance, in May 2024, Amphastar Pharmaceuticals Inc., a U.S.-based pharmaceutical firm, obtained abbreviated new drug application (ANDA) approval from the Food and Drug Administration (FDA) for its albuterol sulfate inhalation aerosol. This product is designed to treat or prevent bronchospasm in patients aged four and older. It acts by relaxing the airway muscles, improving airflow, and providing fast relief from symptoms such as wheezing and difficulty breathing in asthma patients.

In March 2022, Sandoz Group AG, a Switzerland-based pharmaceutical company, acquired Coalesce Product Development Limited for an undisclosed sum. This acquisition is intended to enhance Sandoz’s respiratory portfolio in both the U.S. and European markets. By leveraging Coalesce's expertise in drug delivery systems, Sandoz aims to expand its pipeline of complex respiratory therapies and improve access to high-quality treatment options. Coalesce Product Development Limited is a UK-based firm specializing in the design and development of medical devices, including albuterol sulfate metered-dose inhalers.

Major players in the albuterol sulfate metered dose inhalers market are AstraZeneca PLC, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Sandoz Group AG, Agilent Technologies Inc, AptarGroup Inc., Chiesi Farmaceutici S.p.A., Dr. Reddy's Laboratories, Cipla Limited, Mundipharma International Limited, Lupin Limited, Zydus Pharmaceuticals Inc, Recipharm, Nephron Pharmaceuticals Corporation, Perrigo Company plc, Vectura Group Limited, BioCare Group, Nanopharm Ltd., Prasco Laboratories.

North America was the largest region in the albuterol sulfate metered dose inhalers market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in albuterol sulfate metered dose inhalers report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the albuterol sulfate metered dose inhalers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The albuterol sulfate metered dose inhalers market consists of sales of dry powder inhalers (DPIs), soft mist inhalers (SMIs), nebulizers, and aerosol Inhalers. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment - many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.

The albuterol sulfate metered dose inhalers market research report is one of a series of new reports that provides albuterol sulfate metered dose inhalers market statistics, including the albuterol sulfate metered dose inhalers industry global market size, regional shares, competitors with the albuterol sulfate metered dose inhalers market share, detailed albuterol sulfate metered dose inhalers market segments, market trends, and opportunities, and any further data you may need to thrive in the albuterol sulfate metered dose inhalers industry. This albuterol sulfate metered dose inhalers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Albuterol sulfate metered dose inhalers (MDIs) are compact devices designed to deliver a precise dose of albuterol sulfate directly into the lungs, helping to relax airway muscles, improve airflow, and provide quick relief from breathing difficulties. These inhalers are primarily used to manage and alleviate symptoms of respiratory conditions.

The main types of albuterol sulfate metered dose inhalers include pressurized metered dose inhalers (pMDIs) and breath-activated metered dose inhalers. Pressurized metered-dose inhalers (pMDIs) are portable devices that release an aerosolized dose of medication to the lungs, providing rapid relief for respiratory conditions. These inhalers come in various formulations, including single-unit and multiple-unit dose inhalers. They are distributed through various channels, such as hospital pharmacies, retail pharmacies, online pharmacies, and others, and are used for treating conditions such as asthma, chronic obstructive pulmonary disease (COPD), and more.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.